Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, announces its participation in the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting from April 27-30, 2025, in Boston, MA. The event, which attracts approximately 3,500 international specialists in advanced heart and lung disease treatment, will be held at the John B. Hynes Veterans Memorial Convention Center.
The company will showcase its blood volume analysis technology at Booth 305. According to CEO Michael Feldschuh, their diagnostic solution provides 98% accurate data for personalized treatment in both inpatient and outpatient settings, aimed at improving outcomes while reducing care duration and costs.
Daxor (Nasdaq: DXR), leader mondiale nella tecnologia per la misurazione del volume ematico, annuncia la sua partecipazione al 45° Congresso Annuale della International Society for Heart and Lung Transplant (ISHLT) che si terrà dal 27 al 30 aprile 2025 a Boston, MA. L’evento, che riunisce circa 3.500 specialisti internazionali nel trattamento avanzato delle malattie cardiache e polmonari, si svolgerà presso il John B. Hynes Veterans Memorial Convention Center.
L’azienda presenterà la sua tecnologia di analisi del volume ematico presso lo Stand 305. Secondo il CEO Michael Feldschuh, la loro soluzione diagnostica offre dati con una precisione del 98% per trattamenti personalizzati sia in regime di ricovero che ambulatoriale, con l’obiettivo di migliorare i risultati clinici riducendo la durata e i costi delle cure.
Daxor (Nasdaq: DXR), líder mundial en tecnología de medición del volumen sanguíneo, anuncia su participación en la 45ª Reunión Anual de la International Society for Heart and Lung Transplant (ISHLT) del 27 al 30 de abril de 2025 en Boston, MA. El evento, que reúne a aproximadamente 3,500 especialistas internacionales en el tratamiento avanzado de enfermedades cardíacas y pulmonares, se llevará a cabo en el John B. Hynes Veterans Memorial Convention Center.
La compañía exhibirá su tecnología de análisis de volumen sanguíneo en el Stand 305. Según el CEO Michael Feldschuh, su solución diagnóstica proporciona datos con una precisión del 98% para tratamientos personalizados tanto en pacientes hospitalizados como ambulatorios, con el objetivo de mejorar los resultados y reducir la duración y los costos de la atención.
Daxor (나스닥: DXR)는 혈액량 측정 기술 분야의 세계적인 선두주자로서, 2025년 4월 27일부터 30일까지 매사추세츠주 보스턴에서 열리는 제45회 국제 심장 및 폐 이식 학회(ISHLT) 연례회의에 참가한다고 발표했습니다. 약 3,500명의 심장 및 폐 질환 치료 전문가들이 참석하는 이번 행사는 John B. Hynes Veterans Memorial Convention Center에서 개최됩니다.
회사는 부스 305에서 혈액량 분석 기술을 선보일 예정입니다. CEO 마이클 펠드슈(Michael Feldschuh)에 따르면, 이 진단 솔루션은 입원 환자와 외래 환자 모두에게 맞춤형 치료를 제공하기 위해 98%의 정확한 데이터를 제공하며, 치료 결과를 개선하고 치료 기간과 비용을 줄이는 데 목적이 있습니다.
Daxor (Nasdaq : DXR), leader mondial dans la technologie de mesure du volume sanguin, annonce sa participation à la 45e réunion annuelle de l’International Society for Heart and Lung Transplant (ISHLT) qui se tiendra du 27 au 30 avril 2025 à Boston, MA. L’événement, qui réunit environ 3 500 spécialistes internationaux du traitement avancé des maladies cardiaques et pulmonaires, aura lieu au John B. Hynes Veterans Memorial Convention Center.
L’entreprise présentera sa technologie d’analyse du volume sanguin au stand 305. Selon le PDG Michael Feldschuh, leur solution diagnostique fournit des données précises à 98 % pour un traitement personnalisé en milieu hospitalier et ambulatoire, visant à améliorer les résultats tout en réduisant la durée et le coût des soins.
Daxor (Nasdaq: DXR), der weltweit führende Anbieter von Blutvolumenmessungstechnologie, gibt seine Teilnahme an der 45. Jahrestagung der International Society for Heart and Lung Transplant (ISHLT) bekannt, die vom 27. bis 30. April 2025 in Boston, MA, stattfindet. Die Veranstaltung, die etwa 3.500 internationale Spezialisten für die fortgeschrittene Behandlung von Herz- und Lungenerkrankungen anzieht, wird im John B. Hynes Veterans Memorial Convention Center abgehalten.
Das Unternehmen wird seine Blutvolumenanalysetechnologie am Stand 305 präsentieren. Laut CEO Michael Feldschuh liefert ihre diagnostische Lösung 98 % genaue Daten für personalisierte Behandlungen sowohl im stationären als auch im ambulanten Bereich, mit dem Ziel, die Behandlungsergebnisse zu verbessern und gleichzeitig Behandlungsdauer und -kosten zu reduzieren.
- 98% accuracy rate in blood volume analysis diagnostics
- Technology applicable to both inpatient and outpatient settings
- Potential for cost reduction and improved patient outcomes
- None.
Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum
Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the 45th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions. This premier event gathers approximately 3,500 international specialists in advanced heart and lung disease treatment for four days of innovative research and knowledge exchange. The conference will be held April 27-30, 2025, at the John B. Hynes Veterans Memorial Convention Center in Boston, MA.
"The ISHLT Annual Meeting provides an ideal platform to showcase Daxor's blood volume analysis technology to healthcare teams treating end-stage heart and lung patients," said Michael Feldschuh, CEO of Daxor Corporation. "Our diagnostic delivers
The Company will be exhibiting at Booth 305.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
When and where is Daxor (DXR) presenting at the ISHLT 2025 Annual Meeting?
What is the accuracy rate of Daxor's (DXR) blood volume analysis technology?
How many specialists are expected to attend the ISHLT 2025 conference where Daxor (DXR) is exhibiting?
What are the key benefits of Daxor's (DXR) blood volume analysis technology?
